In prostate cancer patients, Li et al. [17] found that low levels of BDNF-AS were associated with advanced clinical stage high, more lymph node metastasis, and high Gleason score. The gene discussed is BDNF; the disease is metastatic malignant neoplasm in the lymph nodes.